Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990277 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1150080 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL29903285 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL30205136 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL9926899 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL201921 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Alcohol SCHEMBL2569564 | 0.97 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL2886354 | 0.95 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL2886360 | 0.95 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL28786456 | 0.95 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617853-B2 | Ketoreductase polypeptides for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate | CODEXIS, INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20120184000-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,E)-METHYL 2-(3-(3-(2-(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE | CODEXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| EP-2203557-B1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS INC (US) | 2012-02-29 | — | — | EP | claimed |
| EP-2203557-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | Codexis, Inc. (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2009042984-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| US-12233055-B2 | Topical Montelukast formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2025-02-25 | — | — | US | disclosed |
| US-11844861-B2 | Topical Montelukast formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| US-20230248641-A1 | TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-08-10 | — | — | US | disclosed |
| EP-4099982-A1 | TOPICAL MONTELUKAST FORMULATIONS | Taro Pharmaceutical Industries Ltd. (IL) | 2022-12-14 | — | — | EP | disclosed |
| CN-115038427-A | Topical montelukast formulations | 塔罗制药工业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220016028-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2022-01-20 | — | — | US | disclosed |
| US-20210393613-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-12-23 | — | — | US | disclosed |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CHEMAGIS LTD. (IL) | 2007-09-06 | — | — | US | disclosed |
| WO-2007096889-A2 | PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007072114-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
| US-20070082925-A1 | Method for the preparation of montelukast acid and sodium salt thereof in amorphous form | MOREPEN LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | US | disclosed |
| US-20070082925-A1 | Method for the preparation of montelukast acid and sodium salt thereof in amorphous form | MOREPEN LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | US | disclosed |
| US-7189853-B2 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-03-13 | — | — | US | disclosed |
| WO-2007004237-A2 | A PROCESS FOR THE PREPARATION OF MONTELUKAST | MATRIX LABORATORIES LTD (IN) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844861-B2 | Topical Montelukast formulations | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2537/4885CYSLTR2 2/4885 |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | TKT, DCXR, AKR1B1 | CYSLTR1 3689/4885CYP2C8 787/4885CYSLTR2 3723/4885 |
| US-20210393613-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2537/4885CYSLTR2 2/4885 |
| US-12233055-B2 | Topical Montelukast formulations | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2326/4885CYSLTR2 2/4885 |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CYSLTR2, MPST, CMA1 | CYSLTR1 4/4885CYP2C8 1092/4885CYSLTR2 1/4885 |
| US-20070082925-A1 | Method for the preparation of montelukast acid and sodium salt thereof in amorphous form | LTA4H, DACH1, CMA1 | CYSLTR1 5/4885CYP2C8 3876/4885CYSLTR2 7/4885 |
| US-20220016028-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2537/4885CYSLTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.